189 related articles for article (PubMed ID: 19713988)
21. Complicated Clostridium difficile colitis in children with cystic fibrosis: association with gastric acid suppression?
Com G; Cetin N; O'Brien CE
J Cyst Fibros; 2014 Jan; 13(1):37-42. PubMed ID: 23993432
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis.
Arriola V; Tischendorf J; Musuuza J; Barker A; Rozelle JW; Safdar N
Infect Control Hosp Epidemiol; 2016 Dec; 37(12):1408-1417. PubMed ID: 27677811
[TBL] [Abstract][Full Text] [Related]
23. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
McDonald EG; Milligan J; Frenette C; Lee TC
JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
[TBL] [Abstract][Full Text] [Related]
24. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
25. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.
Yu LY; Sun LN; Zhang XH; Li YQ; Yu L; Yuan ZQ; Meng L; Zhang HW; Wang YQ
Adv Ther; 2017 May; 34(5):1070-1086. PubMed ID: 28429247
[TBL] [Abstract][Full Text] [Related]
26. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics.
Lewis PO; Lundberg TS; Tharp JL; Runnels CW
Ann Pharmacother; 2017 Oct; 51(10):848-854. PubMed ID: 28821215
[TBL] [Abstract][Full Text] [Related]
27. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis.
Cadle RM; Mansouri MD; Logan N; Kudva DR; Musher DM
Am J Health Syst Pharm; 2007 Nov; 64(22):2359-63. PubMed ID: 17989446
[TBL] [Abstract][Full Text] [Related]
28. Tube feeding, the microbiota, and Clostridium difficile infection.
O'Keefe SJ
World J Gastroenterol; 2010 Jan; 16(2):139-42. PubMed ID: 20066732
[TBL] [Abstract][Full Text] [Related]
29. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
[TBL] [Abstract][Full Text] [Related]
30. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.
Kim YG; Graham DY; Jang BI
J Clin Gastroenterol; 2012; 46(5):397-400. PubMed ID: 22298089
[TBL] [Abstract][Full Text] [Related]
31. Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment.
Tang YM; Stone CD
Clin J Gastroenterol; 2017 Apr; 10(2):112-123. PubMed ID: 28210836
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections.
Laria A; Zoli A; Gremese E; Ferraccioli GF
Reumatismo; 2011 Mar; 63(1):5-10. PubMed ID: 21509344
[TBL] [Abstract][Full Text] [Related]
33. Does stress ulcer prophylaxis explain the association between clostridium difficile-associated disease and mechanical ventilation?
Porath AD
Chest; 2010 Apr; 137(4):1001; author reply 1001-2. PubMed ID: 20371539
[No Abstract] [Full Text] [Related]
34. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.
Chitnis AS; Holzbauer SM; Belflower RM; Winston LG; Bamberg WM; Lyons C; Farley MM; Dumyati GK; Wilson LE; Beldavs ZG; Dunn JR; Gould LH; MacCannell DR; Gerding DN; McDonald LC; Lessa FC
JAMA Intern Med; 2013 Jul; 173(14):1359-67. PubMed ID: 23780507
[TBL] [Abstract][Full Text] [Related]
35. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.
Moreels N; Boven A; Gressani O; Andersson FL; Vlieghe E; Callens S; Engstrand L; Simin J; Brusselaers N
J Antimicrob Chemother; 2024 Mar; 79(3):608-616. PubMed ID: 38267263
[TBL] [Abstract][Full Text] [Related]
36. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitors and Incident Clostridioides difficile Infection: Beyond Controversy, Pragmatic Approaches Are Needed.
Villafuerte-Gálvez JA
Clin Infect Dis; 2021 Jun; 72(12):e1090-e1092. PubMed ID: 33320187
[No Abstract] [Full Text] [Related]
38. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.
Brown KA; Khanafer N; Daneman N; Fisman DN
Antimicrob Agents Chemother; 2013 May; 57(5):2326-32. PubMed ID: 23478961
[TBL] [Abstract][Full Text] [Related]
39. Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?
Freedberg DE; Abrams JA
Am J Gastroenterol; 2013 Feb; 108(2):278-9. PubMed ID: 23381076
[No Abstract] [Full Text] [Related]
40. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
Barletta JF; Sclar DA
Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
